他莫昔芬在化学激素治疗期间对血清胆固醇和脂蛋白的影响。
Effect of tamoxifen on serum cholesterol and lipoproteins during chemohormonal therapy.
作者信息
Dnistrian A M, Schwartz M K, Greenberg E J, Smith C A, Schwartz D C
机构信息
Department of Clinical Chemistry, Memorial Sloan Kettering Cancer Center, New York, NY 10021.
出版信息
Clin Chim Acta. 1993 Dec 31;223(1-2):43-52. doi: 10.1016/0009-8981(93)90061-8.
The effect of tamoxifen on serum cholesterol, high density lipoprotein cholesterol (HDL-cholesterol), low density lipoprotein cholesterol (LDL-cholesterol) and the ratio of LDL-cholesterol to HDL-cholesterol (LDL-C/HDL-C) was investigated in breast cancer patients undergoing therapy for advanced disease. Longitudinal studies in 24 patients treated with tamoxifen (10 mg, twice daily) indicated average decreases in total serum cholesterol (17%) and LDL-cholesterol (27%), whereas the effect of tamoxifen on HDL-cholesterol varied with the individual patient. There was a significant decrease in the LDL-C/HDL-C ratio (33%) consistent with a decreased risk for coronary artery disease. This beneficial influence of tamoxifen on risk factors associated with cardiovascular disease was evident in both premenopausal and postmenopausal patients whether tamoxifen was administered alone or in combination with cytotoxic chemotherapy.
在接受晚期疾病治疗的乳腺癌患者中，研究了他莫昔芬对血清胆固醇、高密度脂蛋白胆固醇（HDL-胆固醇）、低密度脂蛋白胆固醇（LDL-胆固醇）以及LDL-胆固醇与HDL-胆固醇之比（LDL-C/HDL-C）的影响。对24例接受他莫昔芬治疗（10毫克，每日两次）的患者进行的纵向研究表明，血清总胆固醇平均下降（17%），LDL-胆固醇下降（27%），而他莫昔芬对HDL-胆固醇的影响因个体患者而异。LDL-C/HDL-C比值显著下降（33%），这与冠状动脉疾病风险降低一致。无论他莫昔芬是单独给药还是与细胞毒性化疗联合使用，这种对与心血管疾病相关风险因素的有益影响在绝经前和绝经后患者中均很明显。
Zotero 插件